Biodesix (NASDAQ:BDSX) Earns “Outperform” Rating from William Blair

Biodesix (NASDAQ:BDSX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a research note issued on Tuesday,RTT News reports.

Biodesix Trading Down 1.7 %

Shares of Biodesix stock traded down $0.01 during mid-day trading on Tuesday, hitting $0.70. The stock had a trading volume of 3,248,619 shares, compared to its average volume of 454,421. The firm has a market cap of $101.97 million, a P/E ratio of -1.80 and a beta of 1.06. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The firm has a 50-day moving average of $1.12 and a two-hundred day moving average of $1.42. Biodesix has a 12-month low of $0.64 and a 12-month high of $2.04.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The company had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. Sell-side analysts forecast that Biodesix will post -0.35 earnings per share for the current year.

Insider Buying and Selling at Biodesix

In related news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 128,702 shares of company stock valued at $118,406 over the last 90 days. 69.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its stake in shares of Biodesix by 8.8% in the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after buying an additional 500,000 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Biodesix during the 3rd quarter valued at about $10,849,000. Birchview Capital LP grew its position in Biodesix by 0.7% in the 4th quarter. Birchview Capital LP now owns 5,581,176 shares of the company’s stock valued at $8,539,000 after acquiring an additional 40,000 shares in the last quarter. Silverarc Capital Management LLC increased its stake in Biodesix by 21.7% during the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock worth $6,628,000 after purchasing an additional 771,187 shares during the period. Finally, Samjo Management LLC purchased a new stake in Biodesix during the fourth quarter worth about $3,790,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.